Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-07-24
DOI
10.3389/fonc.2017.00157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy
- (2018) John V. Hegde et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer
- (2017) Phillip J. Gray et al. EUROPEAN UROLOGY
- Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer
- (2016) Elisabeth Rasmusson et al. ACTA ONCOLOGICA
- Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions
- (2016) Giovanni Fellin et al. BRITISH JOURNAL OF RADIOLOGY
- Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012
- (2016) Brock R. Baker et al. CANCER
- Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer
- (2016) Curtis Bryant et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer
- (2015) Zachary S. Zumsteg et al. JOURNAL OF UROLOGY
- Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer
- (2014) Thomas P. Kole et al. ACTA ONCOLOGICA
- Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer
- (2014) D.W. Nathan Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
- (2014) Mekhail Anwar et al. Radiation Oncology
- A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up
- (2014) Constantine Mantz Frontiers in Oncology
- Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival
- (2013) Andrea C. Lo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
- (2013) Matthew J. Resnick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years
- (2013) Alan J Katz et al. Radiation Oncology
- Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes
- (2013) Andrew Loblaw et al. RADIOTHERAPY AND ONCOLOGY
- Hypofractionation for Clinically Localized Prostate Cancer
- (2013) Alvin R. Cabrera et al. SEMINARS IN RADIATION ONCOLOGY
- American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy
- (2012) Brian J. Davis et al. Brachytherapy
- Young age under 60years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer
- (2011) Tracy L. Klayton et al. RADIOTHERAPY AND ONCOLOGY
- Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
- (2011) Siyuan Lei et al. Frontiers in Oncology
- American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy
- (2010) Louis Potters et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer
- (2010) Ryan J. Burri et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- High-Dose Single-Fraction Radiotherapy: Exploiting a New Biology?
- (2008) J. Martin Brown et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Intrafractional Motion of the Prostate During Hypofractionated Radiotherapy
- (2008) Yaoqin Xie et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic Significance of 5-Year PSA Value for Predicting Prostate Cancer Recurrence After Brachytherapy Alone and Combined With Hormonal Therapy and/or External Beam Radiotherapy
- (2008) Richard G. Stock et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?
- (2008) B Furusato et al. JOURNAL OF CLINICAL PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started